LOGO
LOGO

NEXGEL Eyes Over 100% Revenue Growth In 2024 - Will The Stock Get A Facelift?

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

NEXGEL Inc. (NXGL), a provider of medical and over-the-counter products, including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, expects revenue growth of over 100% in 2024 and is optimistic about its outlook for 2025.

The company has partnerships with STADA Arzneimittel AG, a European leader in consumer health; Cintas Corp, a provider of corporate identity uniforms, first aid and safety products, and services; and AbbVie Inc. (ABBV), among others.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - May 04 – May 08, 2026

May 08, 2026 15:50 ET
Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.

RELATED NEWS
Latest Updates on COVID-19